# Mutational signatures driven by epigenetic determinants stratify patients for therapeutic interventions in gastric cancer

Jaqueline Ramalho Buttura<sup>#1</sup>, Monize Nakamoto Provisor<sup>#1,2</sup>, Renan Valieris<sup>1</sup>, Vinicius Fernando Calsavara<sup>3</sup>,Rodrigo Duarte Drummond<sup>1</sup>, Alexandre Defelicibus<sup>1</sup> Joao Paulo Lima<sup>1</sup>, Helano Carioca Freitas<sup>4,5</sup>, Vladmir C. Cordeiro Lima<sup>4</sup>, Thais Fernanda Bartelli<sup>5</sup>, Marc Wiedner<sup>6</sup>, Rafael Rosales<sup>7</sup>, Kenneth John Gollob<sup>8</sup>, Joanna Loizou<sup>6,9</sup>, Emmanuel Dias-Neto<sup>5,10</sup>, Diana Noronha Nunes<sup>5</sup>, Israel Tojal da Silva<sup>1</sup>

<sup>1</sup>Laboratory of Bioinformatics and Computational Biology, A.C.Camargo Cancer Center, So Paulo, SP 01509-010, Brazil.

<sup>2</sup>present address: Department of Genomics, Fleury Group, So Paulo, SP, Brazil. <sup>3</sup>Department of Statistics and Epidemiology, A.C. Camargo Cancer Center, So Paulo, SP, Brazil.

<sup>4</sup>Medical Oncology Department, A.C. Camargo Cancer Center, So Paulo, SP, Brazil. <sup>5</sup>Laboratory of Medical Genomics, A.C. Camargo Cancer Center, So Paulo, SP 01509-010, Brazil.

<sup>6</sup>CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, 1090 Vienna, Austria.

<sup>7</sup>University of So Paulo. Department of Mathematics and Computer Science. 14049-900, Ribeiro Preto, SP, Brazil.

<sup>8</sup> Translational Immuno-oncology Group, A.C. Camargo Cancer Center, So Paulo, SP 01509-010, Brazil.

<sup>9</sup>Institute of Cancer Research, Department of Medicine I, Medical University of Vienna and Comprehensive Cancer Center, Vienna 1090, Austria.

<sup>10</sup>University of So Paulo. Laboratory of Neurosciences, Institute of Psychiatry. So Paulo, SP, Brazil.

# - equal contribution;

## Abstract

DNA mismatch repair deficiency (dMMR) leads to increased mutation load, which in turn may impact anti-tumor immune responses and treatment effectiveness. Currently, there are different mutational signatures described in primary cancers that are associated with dMMR. Whether the somatic and epigenetic changes in MMR genes precede one or more dMMR signa-

Preprint submitted to medRxiv

April 17, 2020

tures, and if so by which mechanism remains unknown. To investigate the relationship between these changes and dMMR signatures, we performed a *de novo* extraction of mutational signatures in a large cohort of 787 gastric cancer patients. We detected three dMMR-related signatures, one of which clearly discriminates tumors with MLH1 gene silencing caused by hypermethylation within its promoter (AUC = 98%). We then demonstrate that samples with the highest exposures to signature share features related to better prognosis, encompassing clinical and molecular aspects, as well as altered immune infiltrate composition, predictive of a better response to immune checkpoint inhibitors. Overall, our analysis explored the impact of modifications in MMR-related genes on shaping specific mutational signatures and we provide evidence that patient classification based on mutational signature exposure can identify a group of patients with a good prognosis and who are potentially good candidates for immunotherapy.

*Keywords:* Mutational Signature, Bioinformatics, Gastric Cancer, DNA, Mismatch Repair Prognosis

## 1 1. Introduction

Cancer results from the sequential accumulation of DNA alterations, in-2 cluding single nucleotide mutations [1] that arise from different endogenous or exogenous processes [2]. Distinct DNA-damaging processes leave characteristic nucleotide base-change footprints known as mutational signatures [3]. 5 Previous studies [4] have extracted distinct mutational signatures by examining a large set of human cancer genomes and some of these have been reported in the COSMIC database (denoted hereafter as CS). This pan-cancer analysis revealed significant heterogeneity of operational mutational processes, a that encompass mutation-triggering events as diverse as the off-target activ-10 ity AID/APOBEC family of cytidine deaminases, the exposure to ultraviolet 11 light, tobacco-smoking and the defective DNA mismatch repair [5, 6]. 12 13

Collectively, the understanding of the mechanistic basis of mutational signatures, as well as to their etiology, may provide clues for cancer diagnosis and hold prognostic value [7]. For example, six mutational signatures have been associated with BRCA1/BRCA2 dysfunction, which most likely are predictive of response to treatment with PARP inhibitors [8]. Thus, homologous recombination repair (HRR)-deficiency features based on these signatures

allowed the prediction of BRCAness in breast cancer patients with 98.7% 20 sensitivity [8]. Additionally, given that nucleotide excision repair (NER) de-21 ficient tumors are more sensitive to certain treatments, somatic variations in 22 the ERCC2 gene, which encodes a key protein of the NER pathway, have 23 also been linked with characteristic mutational signatures [9, 10]. Other mu-24 tational processes are associated with patients harboring biallelic MUTYH 25 germline mutations [11], a finding that may indicate deficient base excision 26 repair (BER). Such patients are eligible for genetic counseling [12] and might 27 benefit from immunotherapy [13]. 28

29

In addition to HRR, NER and BER repair pathways, another mecha-30 nism underlying oncogenic genomic variations, with important effects on 31 anti-tumor immune responses occur in tumors with impaired DNA mismatch 32 repair (MMR), which harbor elevated frequencies of single-nucleotide vari-33 ants (SNVs) and exceptionally high indel rates [14]. Recent studies demon-34 strated that various MMR-deficient (dMMR) tumor types (gastrointestinal, 35 glioblastoma, endometrial and prostate) are more responsive to programmed 36 cell death protein 1 (PD1) immune checkpoint inhibitors as compared to 37 MMR-proficient tumors [15, 16, 17]. A set of four mutational signatures 38 (CS-6, CS-15, CS-20, and CS-26) have been associated with dMMR. Never-39 theless, it is still unclear if somatic and epigenetic changes in MMR genes 40 lead to one or more dMMR signatures. 41

42

In this study we investigated the significance of molecular events in MMR-43 genes that shape characteristic mutation signatures found in MMR-deficient 44 gastric adenocarcinomas. The presence of these signatures was evaluated for 45 their prognostic value in a cohort of 787 gastric cancer patients with pub-46 licly available data, including 439 patients from the TCGA, and validated 47 in a second cohort composed of 170 gastric cancer patients [18]. We fur-48 ther investigated whether local tumor immune response and prognosis varied 49 according to MMR-deficiency exposure load. The consequences of these ap-50 pear to be predictive of the responsiveness to immune checkpoint blockade 51 and may be used to support treatment strategies in the future. 52

## <sup>53</sup> 2. Materials and Methods

#### 54 2.1. Clinical and genomic data from public cohort

The non-redundant public cohorts assessed here contained clinical and 55 molecular information of gastric adenocarcinoma samples provided by: i) 56 The Cancer Genome Atlas (TCGA, N=439), ii) cBioPortal, N=226; iii) and 57 International Cancer Genome Consortium (ICGC, N=122), totaling 787 pa-58 tients (Supplementary Material Table S1). TCGA data was assessed on 59 October  $4^{th}$ , 2018 and corresponds to the MC3 variant calling project, which 60 is a comprehensive effort to detect consensus mutations and forms the basis 61 of Pan-Cancer Atlas initiative [19]. cBioPortal and ICGC cohorts' com-62 prise Asian samples which were last assessed on January  $9^{th}$ , 2019. Raw 63 reads from matched non-tumor exomes from TCGA dataset, encompassing 64 the MMR genes were downloaded and used to detect the germline SNVs 65 following the Genome Analysis Toolkits (GATK)s best practice for germi-66 line alterations calling. We also used additional filters considering mutations 67 with VAF (variant allele frequency)  $\geq 0.3$  and minimum depth coverage of 68 10 reads. Furthermore,  $dbNSFP_MetaLR_rankscore$  was used to filter out 60 (< 0.6) the synonymous mutations. The methylation levels in the form of 70 beta-values ranging from 0 to 1 were addressed for the TCGA cohort [20]. 71 We then used the CpG sites in the promoter of MMR genes to detect those 72 that were hypermethylated or hypomethylated. The baseline clinical features 73 are summarized in Supplementary Material Table S2. 74

#### 75 2.2. Clinical and genomic data from validation cohort

Patients in the validation cohort were prospectively enrolled in an insti-76 tutional study to unveil the epidemiology and genomics of gastric adenocar-77 cinomas in Brazil [18]. This study was approved by the local ethics com-78 mittee and all participants provided written informed consent. An overview 79 of the clinical characteristics of patients in the validation cohort is provided 80 in Table S3. Genomic DNA from frozen tissues (n=165) was extracted with 81 AllPrep DNA/RNA Mini Kit (Qiagen), QIASymphony THC 400 (Qiagen) 82 or phenol/chloroform/isoamyl alcohol precipitation. gDNA from FFPE tis-83 sue (n=4) was extracted with RecoverAll Total Nucleic Acid Isolation Kit 84 (Thermo Fisher), and there was one sample from gastric wash. Exome li-85 braries were prepared using Agilent SureSelect V6 kit and sequenced using Illumina platforms (HiSeq4000, 100bp, n=33; Novaseq, 150bp, n=137 -87

pairedend reads for both). The raw sequencing data (.fastq files) were deposited in SRA (http://www.ncbi.nlm.nih.gov/sra) under accession number
PRJNA505810.

91

For our local independent validation cohort, the somatic SNVs were called 92 by using an in-house pipeline following the Broad Institute GATK Best Prac-93 tices guidelines [21] as described [6]. Briefly, the raw reads were aligned 94 using Burrows Wheeler Aligner (BWA-mem) with default settings to assem-95 bly GRCh38. Next, alignment files in SAM format were converted to BAM 96 files, sorted and filtered to exclude reads with mapp score <15. The re-97 tained reads were processed using SAM tools (v1.9) and Picard (v3.8) (https: 98 //broadinstitute.github.io/picard/) respectively, which excludes low-quality 99 reads and PCR duplicates. Finally, the somatic SNVs calling was performed 100 for the whole exome data from analysis-ready BAM files using Mutect2 (v3.8) 101 for tumor samples and further with a panel of 16 unmatched non-tumor leuko-102 cyte samples. Extensive filtering was applied to remove low mapping quality, 103 as well as strand, position bias and OxoG oxidative artifacts. Furthemore, 104 any residual germline mutations from the database of germline mutations 105 of of gnomAD (https://gnomad.broadinstitute.org/) and Online Archive of 106 Brazilian Mutations (ABraOM, available at http://abraom.ib.usp.br/) were 107 removed. 108

#### 109 2.3. Mutational signatures estimation

All somatic SNVs of the six classes (C>A, C>G, C>T, T>A, T>C and 110 T>G) were mapped onto trinucleotide sequences by including the 5' and 3' 111 neighboring base-contexts. Next, the SNV spectrum with 96 trinucleotide 112 mutations types for all samples were loaded into signeR [22] to estimate 113 the optimal number of mutational signatures, which is based on the me-114 dian Bayesian Information Criterion (BIC) value. We next used the cosine 115 similarity to compare the extracted *de novo* mutational signatures to those 116 described in the COSMIC signatures (v2), considering cosine similarity > 0.7117 as a measure of closeness to COSMIC signatures. Patients with higher ex-118 posure for a given signature (Exposure value greater or equal to the third 119 quartile) were named as *high* and those with lower exposure values (Exposure 120 value less than third quartile) were named as low. 121

## 122 2.4. Molecular features

We used the MSIseq [23] software for microsatellite instability (MSI) sta-123 tus prediction (MSI-H and Non-MSI-H) from whole exome data. Briefly, this 124 software is based on four machine-learning frameworks, which requires a cat-125 alog of somatic SNVs and microindels of samples, a file containing the exact 126 locations of mononucleotides (length>5) and microsatellites consisting of di, 127 tri, and tetranucleotide repeats, as annotated in the simpleRepeats track and 128 avaliable at http://hqdownload.cse.ucsc.edu/qoldenpath/hq19/database/. 129 MSIseq is available at The Comprehensive R Archive Network (CRAN). 130

131

Consistent with a method previously proposed by Chalmers et al. [24], the Tumor Mutational Burden (TMB) was calculated as the total number of mutations divided by the length of the target region in megabases.

135

The tumor heterogeneity estimation was performed using math.score (MATH) function from package maftools version 3.8 [25]. A higher MATH score indicates increased tumor heterogeneity.

139

Neoantigen count: The list of neoantigens available for 77 TCGA-STAD samples was extracted from The Cancer Immunome Atlas (TCIA) [26], assessed on June 17th, 2017 at *https*://tcia.at/neoantigens.

# 143 2.5. Statistical analyses

The baseline patient characteristics are expressed as absolute and relative frequencies for qualitative variables and as the mean  $\pm$  standard deviation (SD) for quantitative variables. Mutational signature exposure and TMB were considered as continuous variables. The association between qualitative variables was evaluated by chi-squared test or Fishers exact test, as appropriate.

150

Overall survival functions were estimated by the Kaplan-Meier estima-151 tor and the log-rank test was used to compare the survival functions among 152 groups (eg, patients with higher mutational signature exposure  $(S^{high})$  ver-153 sus other  $(S^{low})$ ). The Cox semiparametric proportional hazards model was 154 fitted to the dataset to describe the relationship between overall survival and 155 the main clinical features. Hazard ratio (HR) and 95% confidence intervals 156 (95%CI) were calculated for all variables. A backward stepwise selection al-157 gorithm was applied, with different significance levels to enter (p=0.10) and 158

remain (p=0.05) in the model. Variables were removed from the model if they
were non-significant or acted as confounders (change in coefficient >20%).
The proportional hazards assumption was assessed based on the Schoenfeld
residuals [27]. There was evidence that covariates had a constant effect over
time in all cases.

164

Multivariate analyses were performed considering the main clinical fea-165 tures (such as age, pathological stage, Lauren tumor subtype and ethnicity), 166 previously associated with overall survival, and with exposures of mutational 167 signatures associated with dMMR, besides molecular features TMB and MSI 168 status. Forest plots were created based on the final multiple Cox regression 169 model. Metastatic patients were excluded from these analyses. In addition, 170 we fitted simple and multiple logistic regression models in order to assess the 171 effect of S2, S4 and S5 exposures in the *MLH1* methylation. Overall perfor-172 mance, calibration, and the discriminatory power of the final multiple logistic 173 regression model were assessed using the Brier score, the HosmerLemeshow 174 goodness-of-fit test, and the area under the receiver operating characteristic 175 (ROC) curve (AUC), respectively [28]. Besides, we assessed the goodness-of 176 fit through a Q-Q plot. The significance level was fixed at 5% for all tests 177 (two-sided). Statistical analysis was performed using R software (v3.5). 178

## 179 2.6. Mutational signatures in cell lines

The CRISPR-Cas9 knockout clones for *MLH1* were generated in human 180 HAP1 cells using the following guide RNA (gRNA) sequence: 5 - AAGA-181 CAATGGCACCGGGATC - 3. Clonal populations with a frameshift muta-182 tion within MLH1 were subsequently cultured for three months to allow for 183 the accumulation of mutations during cellular division [29]. To identify muta-184 tions, genomic DNA was submitted to whole genome sequencing (WGS). De 185 novo somatic mutations including substitutions, indels and rearrangements 186 in subclones were obtained by removing all mutations seen in parental clones. 187 Next, SNVs were mapped onto trinucleotide sequences by including the 5' 188 and 3' neighboring base-contexts and then the level of samples' exposure to 189 previously found mutational signatures was estimated [22]. 190

## <sup>191</sup> 2.7. Significantly mutated genes and pathway analysis

To assess the impact of dMMR pathway on the genes throughout the genome, we searched for genes more frequently mutated than would be expected by chance [30]. The proper gene symbol annotation in MAF (Mu-

tation Annotation Format) files was addressed by maftools (v.8) [25] (pre-195 pareMutSig function) and then loaded into online MutSigCV server (v.1.3.4) 196 (https: //cloud.genepattern.org/gp/pages/index.jsf). The oncoplots were 197 built by using the significantly mutated genes from MutSigCV analysis. The 198 significantly mutated genes associated to S4<sup>high</sup> and S4<sup>low</sup> group were entered 199 into Gene Set Enrichment Analysis (GSEA) according to the Investigate gene 200 sets function available at MSigDB (Molecular Signatures Database (v7.0). 201 http://software.broadinstitute.org/gsea/msigdb/index.jsp). KEGG, RE-202 ACTOME, GO biological process, oncogenic signatures (module C6) and im-203 munologic signatures (module C7) were also considered to compute overlaps, 204 and the top 20 gene sets with FDR q-value < 0.05 were used to summarize 205 these analysis. 206

## 207 2.8. Inflammatory infiltrate and immune aspects

We estimated the cellular composition from the bulk expression datasets 208 (TCGA) by using two complementary approaches. For both analyses, FPKM 209 (Fragments Per Kilobase Million) from 380 tumor TCGA-STAD samples 210 were used as normalized gene expression profile, retrieved on January  $22^{th}$ . 211 2018. First, the CIBERSORT software based on the deconvolution method 212 for characterizing cell composition of complex tissues from their gene ex-213 pression profiles, was used [31]. CIBESORT takes advantage of a validated 214 leukocyte gene signature matrix, termed LM22. This gene signature contains 215 547 genes that distinguish 22 human hematopoietic cell phenotypes, includ-216 ing seven T cell types, nave and memory B cells, plasma cells, natural killer 217 (NK) cells, and myeloid subsets. Simultaneously, a recent technique based on 218 gene set enrichment analysis (GSEA) termed as xCell [32] was used to infer 219 34 immune cell types. Herein, we used this method to confirm the findings 220 by CIBERSORT. 221

222

CIBERSORT analysis was performed online using a public server (*http*: 223 //cibersort.stanford.edu/) for characterizing absolute and relative immune 224 cell composition with 1000 permutations and disabled quantile normaliza-225 tion as set parameters. From the 380 TCGA-STAD tumor samples, 215 226 215 samples (56%) yielded data on infiltrating immune cells (p-value<0.05), 227 which were considered for further analysis (50 samples as  $S4^{high}$  and 165 as 228 S4<sup>low</sup>). We also used the second approach known as xCell to reinforce the 229 findings when comparing S4<sup>high</sup> and S4<sup>low</sup> samples. xCell analysis was per-230 formed using the R package with default parameters (available at https : 231

//github.com/dviraran/xCell). In order to verify the immune effector response present in S4<sup>high</sup> and S4<sup>low</sup> samples, differential expression of key immunoregulatory/inflammatory or cytotoxic markers was also performed. The comparison of the groups in this section was performed by *Mann-Whitney U* Test with statistical significance set at p-value<0.05.

237

We also used the pre-processed immune subtypes previously described by Thorsson et al. [33] for TCGA samples (available for 103 in  $S4^{high}$  samples and 285 in  $S4^{low}$  which can be assessed in Table S2).

# 241 3. Results

#### 242 3.1. Mutational signatures

Using signeR [22] analysis to estimate *de novo* mutation signatures across 243 three gastric cancer cohorts, we identified seven (denoted hereafter as S[1-7]) 244 mutational signatures (Figure 1A) which are related to signatures described 245 in the COSMIC database by cosine similarity scores (Figure 1B). Signature 246 1 (S1) is associated with endogenous mutational processes initiated by spon-247 taneous deamination of 5-methylcytosine (CS-1); Signatures S2, S4 and S5 248 are associated with defective DNA mismatch repair and/or microsatellite in-240 stability (CS-6/CS-15, CS-20 and CS-21/CS-26 respectively); Signature S3 250 is related with failure of DNA-double strand break repair by homologous re-251 combination (CS-3); Signature S6 related to CS-17 with unknown etiology; 252 and Signature S7 is associated with error-prone polymerase activity (POLE 253 (DNA Polymerase Epsilon, Catalytic Subunit), CS-10). 254

255

CS-3 (S3 in Figure 1 and Figure S1) was the predominant signature found 256 here, supporting previous results which have characterized this signature in 257 gastric cancer samples with a very high prevalence of small indels and base 258 substitutions due to failure of DNA double-strand break repair by homolo-259 gous recombination [34]. This finding suggests that 7-12% of gastric cancers 260 may benefit from either platinum therapy or PARP inhibitors. However, no-261 tably, another group of patients not exposed to signature CS-3 was found to 262 be highly exposed to signatures associated with dMMR (S2, S4 and S5 in 263 Figure S1). Thus, our analysis identified a distinct group of gastric cancer 264 patients harboring features that might have therapeutic relevance and which 265 are further investigated here. 266

Figure 1: *De novo* mutational signatures in gastric cancer. (a) Mutational signatures in gastric cancer from 787 patients from TCGA, ICGC and cbioPortal cohorts. (b) Heatmap with cosine similarities between *de novo* mutational signatures and COSMIC signatures.



(a) Mutational signatures called by signeR.



(b) Heatmap with cosine similarity between *de novo* signatures and COSMIC signatures.

## <sup>267</sup> 3.2. dMMR signatures and prognostic features

We reasoned that dMMR signature exposure could hold prognostic value 268 in gastric cancer. Therefore, we first evaluated the influence of each dMMR 269 signature exposure and the main possible clinical and molecular prognostic 270 features such as age at diagnosis, ethnicity, tumor pathological stage, Lauren 271 classification, anatomic site, TMB and microsatellite instability (MSI) sta-272 tus on overall survival (OS) fitting simple Cox regression model (Figure S2). 273 Data from 584 gastric cancer patients with available vital status information 274 (Alive/Dead) and without metastasis at diagnosis were included in simple 275 and multiple Cox regression models. The median follow-up time for these 276 patients was 28.9 months (with a 95% confidence interval: 95% CI 25.8-32.1) 277 and the mean follow up time was 36.2 months (95% CI 32.9-39.5). 278

279

We then fitted a multiple Cox regression model to the dataset using prognostic features (variables with significant p-value are shown at Figure S2), and observed that S4 exposure burden was associated with improved OS compared with other dMMR signatures (hazard ratio [HR] 0.59 with 95%CI 0.37-0.96) (Figure 2A, Figure S3). Thus, we focused on signature S4, which has the potential to offer important clinically actionable information for treatment selection.

287

Figure 2: Forest plots showing the hazard ratio estimated according to multiple Cox regression models for overall survival.

#### (a) Mutational signature S4



#### (b) Tumor Mutational Burden (TMB)



#### (c) **MSI** status

Variable	N (total)	N (deaths)	Hazard Ratio [95% CI]	I										P-Value
Age	484	188	1.2277 [1.045,1.442]		H									0.012 *
Race (White)	484	188	1.463 [1.092,1.96]		_   <b>⊢</b>	-								0.011 *
Stage II III	484 484	188 188	1.8523 [0.998,3.437] 2.8699 [1.569,5.249]		-		•		-					0.051 0.001 **
MSI-high	484	188	0.7755 [0.508,1.183]	Þ	⊣								_	0.238
				0.5	1	1.5	2 	2.5 Hazard r	3 atio [9	3.5 5% CI]	4	4.5	5	

Our analysis also revealed that a higher TMB was also associated with improved OS (HR=0.66; 95%CI 0.46-0.93) (Figure 2B), consistent with previous studies [35]. Distinctly from TMB, we found no association between predicted MSI-H status and improved OS (HR=0.78; 95%CI 0.51-1.18) (Figure 2C). The calibration curves for these models considering overall survival in 2 years is given in Figure S4, which indicates that all models are adequate.

We used the *maxstat* function (available in R language) to define groups according to the S4 exposure. The optimal cutpoint was within the range of

highest quartile (Q3), and thus patients with S4 exposure >Q3 were labeled 297 as  $S4^{high}$  otherwise  $S4^{low}$  (<Q3). The survival curves from patients in the 298  $S4^{high}$  and  $S4^{low}$  groups were statistically different (p-value < 0.03) with a me-290 dian OS of 72 months (95%CI 48.0- $\infty$ ) in the S4<sup>high</sup> group as compared to 300 37 months (95%CI 28.0-68.0) in the  $S4^{low}$  group (Figure S5). Next, we used 301 an independent gastric cancer cohort to validate that  $S4^{high}$  has a survival 302 benefit. Kaplan-Meier was performed to analyze patients in the validation 303 cohort grouped based on samples' exposure level of signature S4. By com-304 paring patients in the  $S4^{high}$  group whose median OS was not reached at the 305 time of 5 years (95%CI 38.2- $\infty$ ) and the S4<sup>low</sup> group with a median OS of 306 48 months (95%CI 21.3- $\infty$ ), the data indicated a trend toward a survival 307 benefit for S4<sup>*high*</sup> group, supporting our previous findings (Figure S6). 308

## 309 3.3. dMMR signatures associated with MLH1 hypermethylation

Although the genes associated with dMMR are known, the underlying gene modifications that lead to each of the dMMR signatures still remain poorly characterized.

313

To improve our understanding of the determinant changes that influ-314 ence the different dMMR signatures detected in this study, we first looked 315 for somatic and germline SNVs and indels in MMR genes (LIG1, POLE, 316 EXO1, MLH1, MLH3, MSH2, MSH3, MSH5, MSH6, PCNA, PMS1, PMS2, 317 PMS2L3, PMS2L4, POLD1, POLD2, POLD3, POLD4 and SSBP1). We 318 observed that only 6% of patients (12/197) harbored somatic variations in 319 the *MLH1* gene within either  $S2^{high}$  or  $S4^{high}$  groups and no mutated patients 320 within  $S^{low}$  groups. Likewise, our results showed that 9% of the patients in 321 the  $S2^{high}$  group harbored somatic variations in the *MLH3* gene. We also 322 found that only 8% of patients in the  $S5^{high}$  group (8/100 considering TCGA 323 cohort) harbor germline mutations in the MSH5 gene. Altogether, we could 324 observe only few cases harboring mutated MMR genes with some association 325 with the  $S^{high}$  groups. 326

327

We next searched for epigenetic changes in the MMR genes. In line with previous studies [36, 37], we observed downregulation of *MLH1* gene expression driven by hypermethylation of its promoter (Figure S7). To further assess how the mutational exposure is associated with epigenetic changes in the *MLH1* gene, simple and multiple logistic regression models were fitted to the

dataset (Table 1). This analysis revealed that S4 exposure burden was associ-333 ated with an increased chance of MLH1 promoter being methylated (odds ra-334 tio [OR]=22.561; 95%)CI 7.909-64.353). On the other hand, S5 exposure bur-335 den was associated with a decreased chance of MLH1 promoter methylation 336 (OR=0.107; 95%CI 0.048-0.238). Finally, no difference was observed in S2 337 exposure burden (OR=3.682; 95%CI 0.881-15.386). The performance of this 338 model was adequate (HosmerLemeshow goodness-of-fit test  $\chi^2(8)=10.257$ ; 339 p-value=0.247) (Figure 3A), with a good performance observed (Brier score 340 (0.0364), and an excellent power of discrimination (AUC=0.982; 95%CI 0.971-341 0.994) (Figure 3B). Using the Youden index, the best cutoff value (threshold) 342 was 0.125, which had a sensitivity of 95.45% and specificity of 95.82% (Fig-343 ure 3B). 344

345

 Table 1: Simple and multiple logistic regression models for MLH1 methylation

 and dMMR mutational signatures

	Simple logistic regression model											
Variable	Coefficient	Standard Error	CI(95%)	for coefficient	n voluo	OP	CI(95%) for OR					
	Coefficient	Stanuaru Error	Lower Upper		- p-value	on	Lower	Upper				
ExpS2	4.772	0.5226	3.748	5.796	< 0.0001	118.155	42.424	329.078				
ExpS4	3.2424	0.3469	2.562	3.922	< 0.0001	25.595	12.968	50.518				
ExpS5	0.2725	0.1674	-0.056	0.601	0.104	1.313	0.946	1.823				
Multiple logistic regression model												
Variable	Coefficient	Standard Error	CI(95%)	for coefficient	n voluo	OR -	CI(95%) for $OR$					
			Lower	Upper	- p-value		Lower	Upper				
Intercept	-2.640	0.300	-3.227	-2.052	< 0.0001							
ExpS2	1.304	0.730	-0.126	2.733	0.074	3.682	0.881	15.386				
ExpS4	3.1162	0.5348	2.068	4.164	< 0.0001	22.561	7.909	64.353				

Figure 3: **Performance and power discrimination of logistic model.** (a) QQ Plot showing that the propensity score model had an adequate level of calibration according to the Hosmer-Lemeshow test. (b) Summary of ROC curve showing the power of discrimination for *MLH1* methylation at signature S4.



It should be noted that these observations suggest that neither germline 346 SNVs, somatic SNVs or indels are the major modifications affecting gene 347 expression levels, moreover, in fact, MLH1 promoter is hypermethylated in 348 almost 60% of individuals in the S4<sup>*high*</sup> group (beta-value  $\geq 0.3$ ). Taken 349 together, we conclude that the main mechanism of impaired MMR associated 350 with the signature S4 (CS-20) in gastric cancer samples is driven by MLH1351 promoter hypermethylation. Moreover, by using genomic sequencing data 352 from three HAP1 cells samples (2  $MLH1^{KO}$  and 1  $MLH1^{WT}$  cell), we have 353 observed that MLH1<sup>KO</sup> cell lines have higher exposures of the S4 signature, 354 while the parental cell line has higher exposure of the S5 signature (Figure 355 S8), which identifies the absence of MLH1 as the cause of the S4 mutational 356 signature. 357

#### 358 3.4. Clinical and molecular features

Given our observation that the dMMR signature S4 was associated with better prognosis, and possibly related to an epigenetic causative mechanism, we next tried to further characterize the clinical and molecular features within

 $_{362}$  S4<sup>high</sup> and S4<sup>low</sup> groups.

363

Previously defined clinical features that were associated with improved 364 prognosis in gastric cancer were also enriched in the  $S4^{high}$  group (Table 2). 365 such as distal anatomic site and intestinal histology [38]. On the other hand, 366 known clinical variables associated with a worse prognosis in gastric cancer, 367 such as cardia/proximal anatomic site, diffuse histology, positive lymph node 368 metastasis (stage N+) and advanced pathological stages (stage III and IV) 369 [38] were significantly higher in the  $S4^{low}$  group (Table 2). In addition, the 370 predicted MSI-H status, MSI and POLE molecular subtypes were also en-371 riched in the S4<sup>high</sup> group, while genomically stable (GS) and chromosomal 372 instability (CIN) molecular subtypes were enriched in the S4<sup>low</sup> group (Table 373 2). Our data also reveal that most cases of MSI-H (n=119/160, 74%, Table 2)374 were grouped within the S4<sup>high</sup> group, however, it has not escaped from our 375 attention that a smaller fraction of MSI-H cases were unexpectedly grouped 376 in the S4<sup>low</sup> group. Similarly, we have also found Non-MSI-H patients in 377 the S4<sup>high</sup> group. Comparing the survival curves of these groups, we found 378 MSI-H within S4<sup>low</sup> group trends to have a worse prognosis with 9.07 months 379 as median OS (95%CI 9.0- $\infty$ ) than Non-MSI-H within S4<sup>*high*</sup> group with 53 380 months as median OS (95%CI 20.0- $\infty$ ). Similarly, diffuse histologic subtype 381 grouped into S4<sup>*high*</sup> (median OS not reached, 95%CI 24.0- $\infty$ ) trends to have 382 a better prognosis than intestinal histologic subtype grouped into S4<sup>low</sup> (me-383 dian OS of 43.1 months, 95%CI 28.0- $\infty$ ) (Figure S9). Thus, we conclude that 384 the mutational signature classification was able to improve the stratification 385 of patients within the prognostic groups, independent of their previous clin-386 ical or molecular classification. 387

388

To further understand tumor heterogeneity in the  $S4^{high}$  and  $S4^{low}$  pa-389 tients, we examined the spread of allele frequencies according to the quan-390 titative measure of the degree of heterogeneity [39]. We then performed a 391 correlation analysis based on this score, S4 exposure and TMB (Figure 4). 392 We noted that the correlation of the tumor heterogeneity score (MATH) with 393 either TMB or S4 exposure are opposite in the  $S4^{high}$  and  $S4^{low}$  groups. In 394 the S4<sup>high</sup> group, there was a negative correlation of S4 exposure or TMB 395 with MATH and, in the S4<sup>low</sup> group there was a positive correlation. We also 396 observed that the MATH score is higher in the  $S4^{low}$  than the  $S4^{high}$  group 397  $(p-value=3.711 \times 10^{-12})$ . Lastly, the TMB and neoantigen load (by TCIA) 398 have shown a positive correlation with signature S4 exposure in both groups 390

	All(n = 787)		$S4^{low}$	(n = 590)	$S4^{hi}$	$^{gh}(n=197)$	Pualue
	N	%	N	%	N	%	1 Juliuc
Age (mean $\pm$ SD)	64.17	$\pm 11.73$	63.4	$4 \pm 12$	66.5	$25 \pm 10.68$	0.0024
Gender	767	97	571	91	196	99	
Female	274	36	192	34	82	42	0.0472
Male	493	64	379	66	114	58	0.0475
Race	726	92	546	93	180	91	
White	275	28	203	37	72	40	
Black	13	2	11	2	2	1	0 7497
Asian	437	60	331	61	106	59	0.1421
Other	1	0	1	0	0	0	
Anatomic Site	627	80	495	84	132	67	
Cardia/Proximal	168	27	148	30	20	15	
Fundus/Body	212	34	166	34	46	35	0.0015
Antrum/Distal	242	39	178	36	64	48	0.0010
Other	5	1	3	1	2	2	
Histology Lauren	467	59	383	65	84	43	
Diffuse	150	32	132	34	18	21	0.00.11
Intestinal	301	64	235	61	66	79	0.0041
Mixed	16	3	116	4	0	0	
Stage T	712	90	526	89	186	94	
T1 - T2	181	25	132	25	49	26	0.8116
T3 - T4	531	75	394	75	137	74	
Stage N	(12	90	526	89	180	94	
IN U	1/3	24 76	115	22 70	08 199	31	0.0144
N+	039 707	10	411 504	18	128	09	
Stage M	602	90	024 461	09	160	93	
M0 M1	025 69	00	401	00	102	09	0.0422
M I M Y	02	3	47 16	3	15	03	0.9422
Pathological Stago	715	01	546	03	160	86	
	85	91 19	58	95 11	109 97	16	
I II	220	31	160	20	21 60	36	
	220	40	228	23 42	61	36	0.0386
IV	121	15	100	18	21	12	
Molecular Subtype	403	51	289	49	114	58	
CIN	223	55	206	71	17	15	
GS	50	12	47	16			
EBV	38	9		11	5	4	< 0.0001
MSI	85	21	0	0	85	75	
POLE	7	2	3	1	4	4	
MSIseq Status	787	100	590	100	197	100	
MSI - H	160	20	41	7	119	60	<0.0001
Non - MSI - H	627	80	549	93	78	40	<0.0001
Immune Subtype	388	49	285	48	103	52	
C1	128	33	1017	35	27	26	
C2	209	54	135	47	74	72	
C3	35	9	34	12	1	1	< 0.0001
C4	9	2	8	3	1	1	
C6	7	2	7	2	0	0	

Table 2: The clinical-pathological features of gastric cancer according to S4dMMR mutational signature groups

400 (Figure 4).

401

These findings suggest that tumors highly exposed to signature S4 are more homogeneous in the  $S4^{high}$  group and, together with high TMB and high neoantigen load, a reduced tumor heterogeneity appears to be determinant of a good prognosis. In this sense, we speculate that the methylation of *MLH1* promoter associated with the  $S4^{high}$  signature may be an early event in tumorigenesis.

408

In order to check if signature S4 is represented equally across the three cohorts, we compared their samples exposures. To avoid performing statistical tests with different numbers of samples, a subsampling procedure was applied, randomly selecting 24 samples from each cohort and then performing the KruskalWallis test. This was repeated 1000 times, always generating p-values above 0.05, leading us to conclude that the S4 exposure is similar for all cohorts.

# 416 3.5. Significantly mutated genes and related pathways in S4 dMMR groups

MMR-deficiency leads to an elevated frequency of mutations in the genome 417 [14] and the consequences of MMR-deficiency may be derived from func-418 tional alterations in many distinct genes. In order to verify the existence 419 of a common set of genes commonly mutated and their main related path-420 ways between S4<sup>high</sup> and S4<sup>low</sup> groups (Supplementary Material Table S4) 421 we investigated the presence of consistent SNVs differentiating these groups. 422 At least one somatic mutation, including SNVs and indels, was detected for 423 83.25% of  $S4^{high}$  patients, and 78.64% within the  $S4^{low}$  group. We observed 424 an increased number of deletions in the  $S4^{high}$  group, while within the  $S4^{low}$ 425 group the mutations basically consisted of SNVs. These results are expected 426 when considering that MSI/dMMR would lead to a higher number of dele-427 tions [14]. 428

429

The gene set found as significantly mutated in the S4<sup>*high*</sup> group is composed of 102 genes. The most commonly mutated genes in this group are *ARID1A* (42%), *KMT2D* (35%) and *TP53* (31%). In addition, there are another 56 genes presenting mutations in at least 10% of patients (Table S4A). The enrichment analysis of these mutated genes identified pathways related to immune cell differentiation, protein and RNA metabolism, gene expression regulation, cell differentiation and embryogenesis (Table S4B). It was





(c) S4 exposure and MATH (d) S4 exposure and neoantigen score count

<sup>437</sup> previously suggested that somatic mutations in chromatinregulating genes
<sup>438</sup> such as *KMT2D* (also known as *MLL2*) and *ARID1A* are associated with
<sup>439</sup> improved survival [37].

440

In the gene set found as significantly mutated in the  $S4^{low}$  group, 12 out 441 of 24 genes are known oncogenes, associated with tumor progression, or tu-442 mor suppressor genes. These 12 genes are PIK3CA, KRAS, RHOA, CDH1, 443 CTNNB1, ITGAV, SMAD4, TP53, CDKN2A, APC, PTEN and PIK3R1 444 (details in the Table S4C). The most frequently mutated genes in the  $S4^{low}$ 445 group are TP53 (47%), ARID1A (13%) and CDH1 (9%) (Table S4C). The 446 other 21 significantly mutated genes for this group were mutated in up to 447 8% of patients. In addition to the common pathways related to cancer, 448 we also found pathways associated with regulation of cell death, phospho-449 rus metabolism, regulation of transferase activity, morphogenesis pathways 450 (gland development and anatomical structure of a tube) and VEGF and neu-451 rotrophin signaling pathways (Table S4D). 452

453

These findings were in accordance with some genes found previously in 215 non-hypermutated tumors from the TCGA cohort as *APC*, *CTNNB1*, *SMAD4* and *SMAD2*, with somatic mutations in *CDH1* and *RHOA* enriched in the genomically stable and/or diffuse histology [40], subtypes enriched in S4<sup>low</sup> group.

# 459 3.6. Immune diversity in S4 dMMR groups

To investigate a possible role of the immune system being associated with 460 the improved clinical outcomes seen in the  $S4^{high}$  as compared to  $S4^{low}$ , we 461 performed a series of analysis to determine the immune cell infiltrate com-462 position in each group. These analyses used two different analytical method-463 ologies (see Materials and Methods), and demonstrated a significantly higher 464 proportion of infiltrating cytotoxic and pro-inflammatory immune cells in the 465 group S4<sup>high</sup> as exemplified by increased CD8+ central and effector memory 466 T cells, CD4+ memory T cells, Th1 cells, gamma/delta T cells, NK cells, 467 M1 macrophages and plasmacytoid dendritic cells (pDC), as compared to 468 the  $S4^{low}$  group (Figure 5A and S10). In contrast, immature and immune 469 regulatory dendritic cells were higher in the S4<sup>low</sup> group (Figure 5A and S10). 470 471

To further characterize the immune regulatory environment in the S4<sup>*high*</sup> and S4<sup>*low*</sup> groups respectively associated with good or poor clinical outcomes,

Figure 5: The main immunological features associated with  $S4^{high}$  and  $S4^{low}$  groups.



(a) Boxplots showing the absolute quantification of immune infiltrate cells estimated by CIBERSORT (Newman et al., 2015). Blue boxes represent patients in S4<sup>low</sup> group and red those within S4<sup>high</sup> group. Resulting p-values: \*p<0.05; \*\*p<0.01; \*\*\*p<0.001 by Mann-Whitney U test.



(b) Heatmap showing the immune effector genes (cytotoxic and immune checkpoints) expression. Normalized gene expression level (FPKM) for each marker gene was classified in quartiles. Q1 means the range up to first quartile (25% lowest values); Q2: of 25% to 50% (median) expression value; Q3: of 50% to 75% expression values and Q4 means the range of 75% (third quartile) to highest expression values. Left to heatmap, the p value labels consider the *Mann-Whitney U test* by comparing gene expression between S4<sup>high</sup> (red samples) versus S4<sup>low</sup> (blue samples) groups. These comparisons are also shown in Figure S9 as boxplots.

we performed comparisons between gene expression levels of key genes cod-474 ing for immunoregulatory and effector molecules proven to be important for 475 tumor control in many cancers [41, 42]. First, the genes for CD8+T cell 476 related cytolytic molecules Granzyme A/B and Perforin-1 (GZMA, GZMB 477 and PRF1 genes, respectively) all displayed higher expression in the  $S4^{high}$ 478 group (Figures 5B and S11). Moreover, the inflammatory T cell response 479 related cytokine, IFN-gamma (*IFNG* gene) and other proinflammatory cy-480 tokines (IL1B, IL6 and IL8), T cell activation marker genes (IL2RA and 481 ICOS) and NK cell KIR family receptors were also higher in the S4<sup>high</sup> than 482 the S4<sup>low</sup> group (Figures 5B and S11). Second, a series immunosuppression 483 related genes (TGFB1, IL10, and FOXP3) showed no differences between 484 the groups, while *ENTPD1* (CD39 gene), a protein associated with Treg 485 immunosuppression activity [43], was higher in S4<sup>low</sup> vs. S4<sup>high</sup> (Figures 5B 486 and S11). 487

488

Importantly, the expression of the immune checkpoint inhibitor genes 489 (PDCD1 for PD1 receptor, CD274 for PD-L1 ligand, PDCD1LG2 for PD-490 L2, HAVCR2 for TIM3, LAG3 and CTLA4) were also higher in the  $S4^{high}$ 491 group (Figures 5B and S11) possibly indicating a relationship with a more 492 immunologically activated tumor microenvironment [44]. Expression of HLA. 493 antigen processing and presentation-related genes (such as CD86, B2M, vari-494 ous HLA class II genes, HLA-E, HLA-C, TAP1 and TAP2) were also higher 495 in the  $S4^{high}$  group (Figure S11). Together these findings indicate a highly 496 activated immune microenvironment in the  $S4^{high}$  group as compared to the 497  $S4^{low}$  group. 498

499

The immune subtypes previously characterized by Thorsson et al. [33] 500 reinforce the finding that the S4<sup>high</sup> group primarily presents a more immuno-501 logically active tumor microenvironment which is composed predominantly 502 of C2 (interferon-gamma) immune subtype, with a significantly higher pro-503 portion of this subtype as compared to  $S4^{low}$  (Table 2 and Figure 5B). Im-504 portantly, the C2 immune subtype has been associated with highly mutated 505 tumors [33]. On the other hand, the S4<sup>low</sup> group displayed a higher propor-506 tion of C3 (inflammatory) and C1 (wound healing) immune subtypes [33] 507 (Table 2 and Figure 5B). Lastly, the C2 immune subtype in the  $S4^{low}$  group 508 seems to be less activated than in the S4<sup>*high*</sup> group with reduced relative gene 509 expression of immune effector molecules (Figure 5B). 510

# 511 3.7. Discussion

This study provides a comprehensive and integrated analysis of the impact of MMR-related gene alterations in shaping specific mutational signatures associated with gastric cancer. We present evidence that the determination of MMR-deficiency can be used not only for MSI-phenotype classification, but also as a potential indicator of prognosis and to select potential candidates for treatment with checkpoint inhibitors.

518

We performed a *de novo* extraction of mutational signatures based on somatic SNVs across four WES cohorts, spanning 787 gastric cancer samples derived mainly from populations with European and Asian descendance. We found 7 different mutational signatures, with three elated to MMR-deficiency.

Next, we examined the prognostic value of these dMMR signatures in mul-524 tivariate survival analysis by employing a Cox proportional hazards model. 525 This analysis revealed signature S4, related to the previously described CS-526 20, as the only dMMR signature with significant prognostic value. This prog-527 nostic value was validated using our local cohort of gastric cancer patients, 528 distinct in terms of molecular ancestry as well as some clinical and molecular 529 features such as Lauren's histology and tumor heterogeneity. This cohort 530 was predominantly composed of diffuse/mixed histology samples, while pub-531 lic cohorts were enriched for the intestinal subtype. Furthermore, the  $S4^{low}$ 532 group in this independent cohort was less heterogeneous than the  $S4^{low}$  group 533 from the public cohorts and even than the  $S4^{high}$  groups from both cohorts. 534 Nevertheless, we observed a better prognosis for the patients of the  $S4^{high}$ 535 group, also for this cohort. 536

537

Interestingly, after performing a comprehensive analysis of patients ex-538 posed to signature S4 by an in depth evaluation of molecular and immune fea-539 tures, we observed that the main mechanism associated with impaired MMR 540 seems to be the hypermethylation of the MLH1 gene promoter (hMLH1). 541 Moreover, we show that disruption of MLH1 in vitro using CRISPR/Cas9 542 assay reproduces the CS-20 signature [45] that resembles the S4 signature. 543 Here, we have shown an endogenous epigenetic mechanism for this signature 544 in gastric cancer patients. Remarkably, we also reproduce the S4 signature 545 in an isogenic cell model in which the  $MLH1^{KO}$  cells had a high exposure of 546 the S4 signature. Thus importantly, we conclude that independently of the 547 primary mechanism that leads to the loss of MLH1 gene expression - due to 548

promoter hypermethylation or loss of function mutagenesis - it results in the
same mutational signature.

551

It has been well documented that CpG island methylator (CIMP) phe-552 notype is an early event in tumorigenesis, preceding the hMLH1 in solid 553 tumors, which in turn drives the microsatellite instability high (MSI-H) phe-554 notype [36, 40, 37]. In contrast, MSI-low (MSI-L) and microsatellite stable 555 (MSS) gastric carcinoma subtypes have unmethylated *MLH1* promoters and 556 regular MLH1 activity [36]. Here, we classified samples as MSI-H and non-557 MSI-H (MSI-L and MSS) and observed that most cases of MSI-H fall within 558 the S4<sup>high</sup> group, however, a smaller fraction of MSI-H cases did not show 559 high exposure of this mutational signature and were grouped in the  $S4^{low}$ 560 group. This is in line with previous studies showing about one-quarter of 561 the MSI-H cases, despite being MSI-H, present distinct molecular features 562 and poor prognosis [46]. Similarly, we have also found Non-MSI-H patients 563 in the  $S4^{high}$  group, showing that mutational signature exposure is capable 564 of clustering samples independently of their MSI-status. Furthermore, we 565 also identified a few cases (4%) in the S4<sup>high</sup> group that instead of presenting 566 hMLH1, carried somatic mutations in the MLH1 gene that apparently lead 567 to loss-of-function of the encoded protein. Thus, for about 70% of  $\mathrm{S4}^{high}$ 568 cases we found a clear genetic or epigenetic cause. 569 570

We also demonstrated a strong correlation between S4 exposure and 571 TMB, which showed significant prognostic value upon multivariate survival 572 analysis. Hypermutated tumors have been associated with better progno-573 sis and a good response to immunotherapy apparently due to neoantigen 574 enrichment and intrinsic antitumor immune responses [47, 48]. However, a 575 threshold for classifying TMB-high samples usually varies with tumor type 576 [49] and in some cases may not predict a better response [48] due to intratu-577 moral heterogeneity [50]. In this sense, it is important to highlight that most 578 mutations in the  $S4^{high}$  signature are clonal, which is an important feature 579 to predict response to immune checkpoint inhibitors therapy. 580

581

High intratumoral heterogeneity has been associated with an incomplete response to therapy, higher relapse rates, and poor clinical outcomes [51, 52]. The increased genomic instability observed in MSI/dMMR and CIN (chromosomal instability) tumors is the major driver of high intratumoral heterogeneity [53, 51]. However, the most unstable tumors (with the highest burden

of somatic SNVs or copy number alterations) are not the most intrinsically 587 heterogeneous [53]. Furthermore, the greatest intratumor heterogeneity was 588 found in tumors exhibiting relatively high numbers of both somatic muta-589 tions and copy number alterations, which can be associated with exogenous 590 mutagens, including viral infection and tobacco smoking. These tumors have 591 high number of sub-clonal mutations related to late events and exhibit fre-592 quent chromosomal instability associated with CIN subtype, TP53 muta-593 tions, and APOBEC-related mutational signatures (previous related to EBV 594 gastric cancer subtype [6, 53]. Likewise, here we noted that patients with 595 higher S4 exposure harbor more homogeneous tumors as compared to  $S4^{low}$ 596 group. Taken together, the S4<sup>high</sup> group encompassed patients with interme-597 diate to high TMB, in addition to the MSI and CIN molecular phenotypes 598 associated with lower tumor heterogeneity, which might allow for a more ef-599 fective antitumor immune response in this subset of gastric cancer patients. 600 In this sense, a recent meta-analysis discussed the importance of MSI-status 601 for the treatment response in gastric cancer patients, suggesting that MSI-H 602 patients may not benefit from perioperative or adjuvant therapy and could 603 go straight to surgery [54]. 604

605

Finally, several studies have shown that the tumor microenvironment 606 context, at diagnosis, is capable of predicting treatment response and clini-607 cal outcome [55, 56]. The balance of inflammatory/cytotoxic immune cells, 608 with elements of an effective antitumor response, including regulatory cells 609 and suppressor signals, may indicate which patients have an intrinsically 610 effective antitumor response, and thus, a better prognosis. EBV and MSI 611 subtypes in gastric cancer have already been associated with higher immune 612 infiltrate and responsiveness to immunotherapy, as well as better prognosis 613 [55]. Here we found many elements indicating that the tumor microenviron-614 ment in the  $S4^{high}$  group is more active as compared to  $S4^{low}$  patients. In 615 general, the absolute quantification by CIBERSORT [31] or GSEA scores 616 by xCell [32] of immune cell subtypes and the differential gene expression 617 pointed to higher activity of proinflammatory and cytotoxic cells, as well as 618 antigen processing and presentation in  $S4^{high}$ . In contrast, although there 610 were some immunogenic tumors in  $S4^{low}$  group, the predominant environ-620 ment was enriched in Treg lymphocytes and M2 macrophages, both related 621 to worse prognosis [56, 55]. 622

623

In conclusion, while past studies have aimed to identify patients using

molecular and clinical features such as MSI status, TMB load and *MLH1* gene expression levels, our study provides evidence that classification based on mutational signature exposure may identify groups of patients with common clinical, immunological and mutational features that are directly related to a better prognosis, and who might benefit from immunotherapy-based treatments.

#### <sup>631</sup> 3.8. Acknowledgements

This project received financial support from FAPESP (14-26897-0 and 16/11791-7); ED-N and KJG are research fellows from Conselho Nacional de Desenvolvimento Científico e Tecnolgico (CNPq, Brazil). ED-N acknowledges the support given by Associação Beneficente Alzira Denise Hertzog Silva (ABADHS).

#### 637 References

- [1] M. R. Stratton, P. J. Campbell, P. A. Futreal, The cancer genome, Nature 458 (2009) 719–724.
- [2] R. Hakem, DNA-damage repair; the good, the bad, and the ugly, EMBO
   J. 27 (2008) 589–605.
- [3] T. Helleday, S. Eshtad, S. Nik-Zainal, Mechanisms underlying mutational signatures in human cancers, Nat. Rev. Genet. 15 (2014) 585–598.
- [4] L. B. Alexandrov, S. Nik-Zainal, D. C. Wedge, S. A. Aparicio, S. Behjati,
   A. V. Biankin, et al., Signatures of mutational processes in human cancer, Nature 500 (2013) 415–421.
- [5] M. Hollstein, L. B. Alexandrov, C. P. Wild, M. Ardin, J. Zavadil, Base changes in tumour DNA have the power to reveal the causes and evolution of cancer, Oncogene 36 (2017) 158–167.
- [6] I. Bobrovnitchaia, R. Valieris, R. D. Drummond, J. P. Lima, H. C.
  Freitas, T. F. Bartelli, et al., APOBEC-mediated DNA alterations: A possible new mechanism of carcinogenesis in EBV-positive gastric cancer, Int. J. Cancer 146 (2020) 181–191.
- [7] A. Van Hoeck, N. H. Tjoonk, R. van Boxtel, E. Cuppen, Portrait of
   a cancer: mutational signature analyses for cancer diagnostics, BMC
   Cancer 19 (2019) 457.

- [8] H. Davies, D. Glodzik, S. Morganella, L. R. Yates, J. Staaf, X. Zou,
  et al., HRDetect is a predictor of BRCA1 and BRCA2 deficiency based
  on mutational signatures, Nat. Med. 23 (2017) 517–525.
- [9] J. Kim, K. W. Mouw, P. Polak, L. Z. Braunstein, A. Kamburov, D. J. Kwiatkowski, et al., Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors, Nat. Genet. 48 (2016) 600–606.
- [10] M. Jager, F. Blokzijl, E. Kuijk, J. Bertl, M. Vougioukalaki, R. Janssen,
  et al., Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer, Genome Res. 29 (2019) 1067–1077.
- [11] M. L. Thibodeau, E. Y. Zhao, C. Reisle, C. Ch'ng, H. L. Wong, Y. Shen,
  et al., Base excision repair deficiency signatures implicate germline and
  somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and
  breast cancer oncogenesis, Cold Spring Harb Mol Case Stud 5 (2019).
- [12] M. D. Giraldez, F. Balaguer, L. Bujanda, M. Cuatrecasas, J. Mu?oz,
  V. Alonso-Espinaco, et al., MSH6 and MUTYH deficiency is a frequent
  event in early-onset colorectal cancer, Clin. Cancer Res. 16 (2010) 5402–
  5413.
- [13] N. M. Volkov, G. A. Yanus, A. O. Ivantsov, F. V. Moiseenko, O. G.
  Matorina, I. V. Bizin, et al., Efficacy of immune checkpoint blockade
  in MUTYH-associated hereditary colorectal cancer, Invest New Drugs
  (2019).
- [14] R. Mandal, R. M. Samstein, K. W. Lee, J. J. Havel, H. Wang, C. Krishna, et al., Genetic diversity of tumors with mismatch repair deficiency
  influences anti-PD-1 immunotherapy response, Science 364 (2019) 485–
  491.
- [15] D. T. Le, J. N. Durham, K. N. Smith, H. Wang, B. R. Bartlett, L. K.
  Aulakh, et al., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science 357 (2017) 409–413.
- [16] W. Abida, M. L. Cheng, J. Armenia, S. Middha, K. A. Autio, H. A.
  Vargas, et al., Analysis of the Prevalence of Microsatellite Instability in
  Prostate Cancer and Response to Immune Checkpoint Blockade, JAMA
  Oncol 5 (2019) 471–478.

- [17] Z. R. Reichert, J. Urrutia, J. J. Alumkal, Microsatellite Instability as
   an Emerging Biomarker for Checkpoint Inhibitor Response in Advanced
   Prostate Cancer, JAMA Oncol 5 (2019) 478–479.
- [18] GE4GACgroup, T. Bartelli, et al., Genomics and epidemiology for gas tric adenocarcinomas (GE4GAC): a Brazilian initiative to study gastric
   cancer, Appl. Cancer Res. 39 (2019).
- [19] K. Ellrott, M. Bailey, G. Saksena, K. Covington, C. Kandoth, C. Stewart, et al., Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines, Cell Syst. 28 (2018) 271–281.
- [20] G. Ciriello, M. L. Miller, B. A. Aksoy, Y. Senbabaoglu, N. Schultz,
  C. Sander, Emerging landscape of oncogenic signatures across human cancers, Nat. Genet. 45 (2013) 1127–1133.
- [21] M. A. DePristo, E. Banks, R. Poplin, K. V. Garimella, J. R. Maguire,
  C. Hartl, et al., A framework for variation discovery and genotyping
  using next-generation DNA sequencing data, Nat. Genet. 43 (2011)
  491–498.
- R. A. Rosales, R. D. Drummond, R. Valieris, E. Dias-Neto, I. T. da Silva,
  signeR: an empirical Bayesian approach to mutational signature discovery, Bioinformatics 33 (2017) 8–16.
- [23] M. N. Huang, J. R. McPherson, I. Cutcutache, B. T. Teh, P. Tan, S. G.
  Rozen, MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations, Sci Rep 5 (2015) 13321.
- [24] Z. R. Chalmers, C. F. Connelly, D. Fabrizio, L. Gay, S. M. Ali, R. Ennis,
  et al., Analysis of 100,000 human cancer genomes reveals the landscape
  of tumor mutational burden, Genome Med 9 (2017) 34.
- [25] A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, H. P. Koeffler, Maftools:
  efficient and comprehensive analysis of somatic variants in cancer,
  Genome Res. 28 (2018) 1747–1756.
- [26] P. Charoentong, F. Finotello, M. Angelova, C. Mayer, M. Efremova, D. Rieder, et al., Pan-cancer Immunogenomic Analyses Reveal
  Genotype-Immunophenotype Relationships and Predictors of Response
  to Checkpoint Blockade, Cell Rep 18 (2017) 248–262.

- [27] D. Schoenfeld, Partial residuals for the proportional hazards regression
   model., Biometrika 69 (1982) 239–241.
- [28] D. Hosmer, S. Lemeshow, S. RX., Applied Logistic Regression., Wiley
  3 edition (2013).
- [29] X. Zou, M. Owusu, R. Harris, S. P. Jackson, J. I. Loizou, S. Nik-Zainal,
  Validating the concept of mutational signatures with isogenic cell models, Nat Commun 9 (2018) 1744.
- [30] M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis,
  A. Sivachenko, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature 499 (2013) 214–218.
- [31] A. M. Newman, C. L. Liu, M. R. Green, A. J. Gentles, W. Feng, Y. Xu,
  et al., Robust enumeration of cell subsets from tissue expression profiles,
  Nat. Methods 12 (2015) 453–457.
- [32] D. Aran, Z. Hu, A. J. Butte, xCell: digitally portraying the tissue cellular heterogeneity landscape, Genome Biol. 18 (2017) 220.
- [33] V. Thorsson, D. Gibbs, S. Brown, D. Wolf, D. Bortone, T. Ou Yang,
  et al., The Immune Landscape of Cancer, Immunity 51 (2019) 411–412.
- [34] L. B. Alexandrov, S. Nik-Zainal, H. C. Siu, S. Y. Leung, M. R. Stratton,
  A mutational signature in gastric cancer suggests therapeutic strategies,
  Nat Commun 6 (2015) 8683.
- [35] R. Buttner, J. W. Longshore, F. Lopez-Rios, S. Merkelbach-Bruse,
  N. Normanno, E. e. a. Rouleau, Implementing TMB measurement in clinical practice: considerations on assay requirements, ESMO Open 4 (2019) e000442.
- [36] S. Y. Leung, S. T. Yuen, L. P. Chung, K. M. Chu, A. S. Chan, J. C. Ho, hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability, Cancer Res. 59 (1999) 159–164.
- [37] W. Hu, Y. Yang, L. Qi, J. Chen, W. Ge, S. Zheng, Subtyping of microsatellite instability-high colorectal cancer, Cell Commun. Signal 17 (2019) 79.

- [38] G. Cammerer, A. Formentini, M. Karletshofer, D. Henne-Bruns, M. Kornmann, Evaluation of important prognostic clinical and pathological
  factors in gastric cancer, Anticancer Res. 32 (2012) 1839–1842.
- [39] A. Rajput, T. Bocklage, A. Greenbaum, J. H. Lee, S. A. Ness, MutantAllele Tumor Heterogeneity Scores Correlate With Risk of Metastases
  in Colon Cancer, Clin Colorectal Cancer 16 (2017) e165–e170.
- [40] A. J. Bass, V. Thorsson, I. Shmulevich, S. M. Reynolds, M. Miller,
  B. Bernard, T. Hinoue, et al., Comprehensive molecular characterization of gastric adenocarcinoma, Nature 513 (2014) 202–209.
- [41] G. Landskron, M. De la Fuente, P. Thuwajit, C. Thuwajit, M. A. Hermoso, Chronic inflammation and cytokines in the tumor microenvironment, J Immunol Res 2014 (2014) 149185.
- [42] S. A. Fuertes Marraco, N. J. Neubert, G. Verdeil, D. E. Speiser, Inhibitory Receptors Beyond T Cell Exhaustion, Front Immunol 6 (2015)
  310.
- [43] J. Bastid, A. Cottalorda-Regairaz, G. Alberici, N. Bonnefoy, J. F.
  Eliaou, A. Bensussan, ENTPD1/CD39 is a promising therapeutic target in oncology, Oncogene 32 (2013) 1743–1751.
- [44] M. Binnewies, E. W. Roberts, K. Kersten, V. Chan, D. F. Fearon,
  M. Merad, et al., Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat. Med. 24 (2018) 541–550.
- [45] J. Drost, R. van Boxtel, F. Blokzijl, T. Mizutani, N. Sasaki, V. Sasselli,
  et al., Use of CRISPR-modified human stem cell organoids to study the
  origin of mutational signatures in cancer, Science 358 (2017) 234–238.
- [46] W. Hu, Y. Yang, L. Qi, J. Chen, W. Ge, S. Zheng, Subtyping of microsatellite instability-high colorectal cancer, Cell Commun. Signal 17 (2019) 79.
- [47] A. M. Goodman, S. Kato, L. Bazhenova, S. P. Patel, G. M. Frampton,
  V. Miller, et al., Tumor Mutational Burden as an Independent Predictor
  of Response to Immunotherapy in Diverse Cancers, Mol. Cancer Ther.
  16 (2017) 2598–2608.

- [48] S. Mishima, A. Kawazoe, Y. Nakamura, A. Sasaki, D. Kotani,
  Y. Kuboki, et al., Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer, J
  Immunother Cancer 7 (2019) 24.
- [49] R. M. Samstein, C. H. Lee, A. N. Shoushtari, M. D. Hellmann, R. Shen,
  Y. Y. Janjigian, et al., Tumor mutational load predicts survival after
  immunotherapy across multiple cancer types, Nat. Genet. 51 (2019)
  202–206.
- [50] Q. Jia, W. Wu, Y. Wang, P. B. Alexander, C. Sun, Z. Gong, et al.,
  Local mutational diversity drives intratumoral immune heterogeneity in
  non-small cell lung cancer, Nat Commun 9 (2018) 5361.
- [51] G. Stanta, S. Bonin, Overview on Clinical Relevance of Intra-Tumor
   Heterogeneity, Front Med (Lausanne) 5 (2018) 85.
- <sup>797</sup> [52] A. C. F. Bolhaqueiro, B. Ponsioen, B. Bakker, S. J. Klaasen, E. Ku-<sup>798</sup> cukkose, R. H. van Jaarsveld, et al., Ongoing chromosomal instability <sup>799</sup> and karyotype evolution in human colorectal cancer organoids, Nat. <sup>800</sup> Genet. 51 (2019) 824–834.
- [53] F. Raynaud, M. Mina, D. Tavernari, G. Ciriello, Pan-cancer inference
   of intra-tumor heterogeneity reveals associations with different forms of
   genomic instability, PLoS Genet. 14 (2018) e1007669.
- <sup>804</sup> [54] F. Pietrantonio, R. Miceli, A. Raimondi, Y. W. Kim, W. K. Kang, R. E.
  <sup>805</sup> Langley, et al., Individual Patient Data Meta-Analysis of the Value of
  <sup>806</sup> Microsatellite Instability As a Biomarker in Gastric Cancer, J. Clin.
  <sup>807</sup> Oncol. 37 (2019) 3392–3400.
- [55] M. Wang, R. A. Busuttil, S. Pattison, P. J. Neeson, A. Boussioutas,
  Immunological battlefield in gastric cancer and role of immunotherapies,
  World J. Gastroenterol. 22 (2016) 6373–6384.
- <sup>811</sup> [56] W. H. Fridman, L. Zitvogel, C. Saut?s-Fridman, G. Kroemer, The immune contexture in cancer prognosis and treatment, Nat Rev Clin Oncol 14 (2017) 717–734.